Dr. Johnson and Dr. Bahçe-Altuntaş reply

REFERENCES

1. 1.↵
   1. Johnson BK,
   2. Bahçe-Altuntaş A

   . Too little too late: effect of poor access to biologics for patients with rheumatoid arthritis. J Rheumatol 2017;44:1765–6.

   OpenUrlFREE Full Text
2. 2.↵
   1. Stamp LK,
   2. Haslett J,
   3. Chapman P,
   4. O’Donnell J,
   5. Raja R,
   6. Rothwell A,
   7. et al.

   Rates of joint replacement surgery in New Zealand, 1999–2015: a comparison of rheumatoid arthritis and osteoarthritis. J Rheumatol 2017;44:1823–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Boers M

   . Excessive pricing causes poor access to biologics. J Rheumatol 2018;45:876–7.

   OpenUrlFREE Full Text
4. 4.↵
   1. Smolen JS,
   2. Landewé R,
   3. Bijlsma J,
   4. Burmester G,
   5. Chatzidionysiou K,
   6. Dougados M,
   7. et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Singh JA,
   2. Saag KG,
   3. Bridges SL,
   4. Akl EA,
   5. Bannuru RR,
   6. Sullivan MC,
   7. et al.

   2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1–25.

   OpenUrlCrossRef